Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the
submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:90532519
Filing Date:02/17/2021
To the Commissioner for Trademarks:
MARK: CAVIVA (Standard Characters, see mark)
The literal element of the mark consists of CAVIVA. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, AstraZeneca AB, a aktiebolag (ab) legally organized under the laws of Sweden, having an address of
Astraallén
Södertälje SE-15185
Sweden
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 005: Pharmaceutical preparations and substances
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of
priority based on European Union Trademark - EUTM application number 018299584, filed 08/31/2020.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the
foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.
The owner's/holder's proposed attorney information: Wm. Charles Saunders. Wm. Charles Saunders of AstraZeneca Pharmaceuticals LP, is a member of the XX bar, admitted to the bar in XXXX, bar
membership no. XXX, is located at
A2C
1800 Concord Pike
Wilmington, Delaware 19850-5437
United States
302-886-6934(phone)
3028853762(fax)
chuck.saunders@astrazeneca.com
The docket/reference number is 103885/US.
Wm. Charles Saunders submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any
U.S. Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).
Declaration
Declaration Signature
Signature: /wcs/ Date: 02/17/2021
Signatory's Name: Wm. Charles Saunders
Signatory's Position: Attorney of record, Pennsylvania Bar member
Signatory's Phone Number: 302-886-6934
Signature method: Sent to third party for signature
Payment Sale Number: 90532519
Payment Accounting Date: 02/17/2021
Serial Number: 90532519
Internet Transmission Date: Wed Feb 17 16:25:13 ET 2021
TEAS Stamp: USPTO/BAS-XX.XXX.XX.XXX-2021021716251367
5587-90532519-77062b59c1a855bf7594470d88
4ccfcb863c12d855acdf277e1c3d01b14e1f7c6d
8-DA-25133578-20210217100416203142